View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 4, 2021updated 28 Oct 2021 1:06pm

Merck-Ridgeback’s oral drug lowers hospitalisation risk in Covid-19 trial

In the Phase III trial, no deaths were observed in the molnupiravir arm as against eight in the placebo group through day 29. 

Merck (MSD) and Ridgeback Biotherapeutics have reported that their oral drug, molnupiravir (MK-4482, EIDD-2801), substantially lowered the hospitalisation or mortality risk in the Phase III MOVe-OUT clinical trial in adults with mild-to-moderate Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The experimental antiviral medicine molnupiravir is an oral formulation of a ribonucleoside analogue that can potentially hinder Covid-19 causing SARS-CoV-2 virus replication.

The international, randomised, double-blind, placebo-controlled, multicentre Phase III trial analysed Covid-19 patients in the non-hospital setting with a minimum of one risk factor linked to reduced outcomes and the presence of symptoms in the five days before randomisation.

Analysing the oral antiviral’s efficacy versus placebo as evaluated by the percentage of subject hospitalisation and/or death from the randomisation time until day 29 was the primary efficacy goal of the trial.

The Phase III part was carried out globally, including in over 170 planned trial centres in nations including Argentina, Canada, Brazil, South Africa, the UK and the US, among others.

According to an interim analysis assessing results from 775 subjects, molnupiravir lowered hospitalisation or mortality risk by nearly 50%.

Furthermore, nearly 7.3% in the molnupiravir arm were in hospital or died by day 29 as against 14.1% in the placebo arm.

No cases of mortality were observed in the molnupiravir group versus eight in the placebo group through day 29.

According to the Independent Data Monitoring Committee’s (IDMC) recommendation and discussions with the US Food and Drug Administration (FDA), enrolment will be halted at an earlier time point on obtaining positive data from the trial.

Merck shortly intends to seek Emergency Use Authorization (EUA) from the FDA and marketing approvals from other drug regulators globally.

Merck CEO and president Robert Davis said: “With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck’s unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most.

“Consistent with Merck’s unwavering commitment to save and improve lives, we will continue to work with regulatory agencies on our applications and do everything we can to bring molnupiravir to patients as quickly as possible.”

In August, Merck started a rolling submission to Health Canada for molnupiravir as a potential Covid-19 therapy.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology